|Rapid Review Complete
|Macitentan is indicated as monotherapy or in combination, for the long term treatment of pulmonary arterial hypertension (PAH) in adult patients of WHO Functional Class (FC) II to III.
|Rapid review commissioned
|Rapid review completed
|Rapid review outcome
|Full Pharmacoeconomic Evaluation not Recommended